Home LiteratureArticle Details
PMID: 19214216 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants.

PLoS pathogens ·Vol. 5 ·No. 2 ·2009-02-00 ·Pages e1000300

McNatt MW, Zang T, Hatziioannou T, Bartlett M, Fofana IB, Johnson WE, Neil SJ, Bieniasz PD

Abstract

Tetherin/BST-2/CD317 is a recently identified antiviral protein that blocks the release of nascent retrovirus, and other virus, particles from infected cells. An HIV-1 accessory protein, Vpu, acts as an antagonist of tetherin. Here, we show that positive selection is evident in primate tetherin sequences and that HIV-1 Vpu appears to have specifically adapted to antagonize variants of tetherin found in humans and chimpanzees. Tetherin variants found in rhesus macaques (rh), African green monkeys (agm) and mice were able to inhibit HIV-1 particle release, but were resistant to antagonism by HIV-1 Vpu. Notably, reciprocal exchange of transmembrane domains between human and monkey tetherins conferred sensitivity and resistance to Vpu, identifying this protein domain as a critical determinant of Vpu function. Indeed, differences between hu-tetherin and rh-tetherin at several positions in the transmembrane domain affected sensitivity to antagonism by Vpu. Two alterations in the hu-tetherin transmembrane domain, that correspond to differences found in rh- and agm-tetherin proteins, were sufficient to render hu-tetherin completely resistant to HIV-1 Vpu. Interestingly, transmembrane and cytoplasmic domain sequences in primate tetherins exhibit variation at numerous codons that is likely the result of positive selection, and some of these changes coincide with determinants of HIV-1 Vpu sensitivity. Overall, these data indicate that tetherin could impose a barrier to viral zoonosis as a consequence of positive selection that has been driven by ancient viral antagonists, and that the HIV-1 Vpu protein has specialized to target the transmembrane domains found in human/chimpanzee tetherin proteins.

MeSH Terms
Animals Antigens, CD/genetics,metabolism Cell Line Chlorocebus aethiops Evolution, Molecular GPI-Linked Proteins Human Immunodeficiency Virus Proteins/antagonists & inhibitors,physiology Humans Macaca mulatta Membrane Glycoproteins/genetics,metabolism Mice NIH 3T3 Cells Pan troglodytes Polymorphism, Genetic Protein Structure, Tertiary/genetics Selection, Genetic Species Specificity Viral Regulatory and Accessory Proteins/antagonists & inhibitors,physiology Virion/metabolism
Chemicals
Antigens, CD BST2 protein, human GPI-Linked Proteins Human Immunodeficiency Virus Proteins Membrane Glycoproteins Viral Regulatory and Accessory Proteins vpu protein, Human immunodeficiency virus 1
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
McNatt Matthew W
Aaron Diamond AIDS Research Center and The Rockefeller University, New York, New York, United States of America.
Zang Trinity
Hatziioannou Theodora
Bartlett Mackenzie
Fofana Ismael Ben
Johnson Welkin E
Neil Stuart J D
Bieniasz Paul D
References (24)
24 references, click to expand
  1. Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production.
    J Virol. 2005 Mar;79(6):3627-38 PMID: 15731257
  2. Antiviral actions of interferons.
    Clin Microbiol Rev. 2001 Oct;14(4):778-809, table of contents PMID: 11585785
  3. The two biological activities of human immunodeficiency virus type 1 Vpu protein involve two separable structural domains.
    J Virol. 1996 Feb;70(2):809-19 PMID: 8551619
  4. The envelope glycoprotein of human immunodeficiency virus type 2 enhances viral particle release: a Vpu-like factor?
    J Virol. 1996 Feb;70(2):820-9 PMID: 8551620
  5. HIV-1 Vpu promotes release and prevents endocytosis of nascent retrovirus particles from the plasma membrane.
    PLoS Pathog. 2006 May;2(5):e39 PMID: 16699598
  6. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin.
    J Virol. 2009 Feb;83(4):1837-44 PMID: 19036818
  7. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.
    Nature. 2008 Jan 24;451(7177):425-30 PMID: 18200009
  8. An interferon-alpha-induced tethering mechanism inhibits HIV-1 and Ebola virus particle release but is counteracted by the HIV-1 Vpu protein.
    Cell Host Microbe. 2007 Sep 13;2(3):193-203 PMID: 18005734
  9. Ancient adaptive evolution of the primate antiviral DNA-editing enzyme APOBEC3G.
    PLoS Biol. 2004 Sep;2(9):E275 PMID: 15269786
  10. Identification of calcium-modulating cyclophilin ligand as a human host restriction to HIV-1 release overcome by Vpu.
    Nat Med. 2008 Jun;14(6):641-7 PMID: 18500349
  11. The B30.2(SPRY) domain of the retroviral restriction factor TRIM5alpha exhibits lineage-specific length and sequence variation in primates.
    J Virol. 2005 May;79(10):6111-21 PMID: 15857996
  12. Functional role of human immunodeficiency virus type 1 vpu.
    Proc Natl Acad Sci U S A. 1989 Jul;86(13):5163-7 PMID: 2472639
  13. Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology.
    Traffic. 2003 Oct;4(10):694-709 PMID: 12956872
  14. Datamonkey: rapid detection of selective pressure on individual sites of codon alignments.
    Bioinformatics. 2005 May 15;21(10):2531-3 PMID: 15713735
  15. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.
    Cell Host Microbe. 2008 Apr 17;3(4):245-52 PMID: 18342597
  16. Molecular and biochemical analyses of human immunodeficiency virus type 1 vpu protein.
    J Virol. 1989 Sep;63(9):3784-91 PMID: 2788224
  17. Viral protein U counteracts a human host cell restriction that inhibits HIV-1 particle production.
    Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15154-9 PMID: 14657387
  18. Cell type-dependence for Vpu function.
    J Med Primatol. 1994 Feb-May;23(2-3):146-50 PMID: 7966229
  19. Positive selection of primate TRIM5alpha identifies a critical species-specific retroviral restriction domain.
    Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2832-7 PMID: 15689398
  20. PAML 4: phylogenetic analysis by maximum likelihood.
    Mol Biol Evol. 2007 Aug;24(8):1586-91 PMID: 17483113
  21. Quantitative membrane proteomics reveals new cellular targets of viral immune modulators.
    PLoS Pathog. 2006 Oct;2(10):e107 PMID: 17238276
  22. PAML: a program package for phylogenetic analysis by maximum likelihood.
    Comput Appl Biosci. 1997 Oct;13(5):555-6 PMID: 9367129
  23. Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following IFN stimulation.
    J Immunol. 2006 Sep 1;177(5):3260-5 PMID: 16920966
  24. Type I interferons in host defense.
    Immunity. 2006 Sep;25(3):373-81 PMID: 16979569
Article Info
Journal
PLoS pathogens
Abbr.
PLoS Pathog
ISSN
1553-7374
Published
2009-02-00
Epub
2009-00-13
Pages
e1000300
Language
English
Region
United States
NLM ID
101238921
PMCID
PMC2633611
Subset
IM
Grants
NIAID NIH HHS · R01 AI078788 · United States
NCRR NIH HHS · RR00168 · United States
NIAID NIH HHS · R01AI 050111 · United States
NIAID NIH HHS · R01 AI050111 · United States
NIAID NIH HHS · R01AI078788 · United States
NCRR NIH HHS · P51 RR000168 · United States
NCRR NIH HHS · K26 RR000168 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]